Niagen Bioscience (NAGE) just posted its Q1 2026 numbers, with revenue of US$31.5 million and basic EPS of US$0.08, setting the tone for how the year is starting to shape up on the top and bottom line. The company has seen quarterly revenue move from US$29.1 million in Q4 2024 to a range of roughly US$30.5 million to US$34.0 million through 2025, while basic EPS has run between US$0.05 and US$0.09 over the same stretch, giving you a clearer feel for how Q1 2026 fits into the recent trend. With a trailing twelve month net profit margin of 14.3% and improving efficiency versus the prior year, the latest print keeps the focus firmly on how durable those margins prove to be.

See our full analysis for Niagen Bioscience.

With the quarterly figures on the table, the next step is to set these results against the prevailing narratives and see where the data supports the story and where it starts to challenge expectations.

Net Income Steps Up Even As Revenue Mix Shifts

• Net income excluding extra items in Q1 2026 was US$6.3 million, higher than any quarter in 2025 despite revenue of US$31.5 million sitting below the Q3 and Q4 2025 levels of roughly US$34.0 million and US$33.8 million.
• What stands out for a more bullish take is that trailing 12 month earnings grew 32.1% to US$18.6 million while net profit margin improved from 13.1% to 14.3%. However, this period also includes a US$6.8 million one off gain that bullish investors need to adjust for when judging how much of the earnings strength is repeatable.
  • The trailing 12 month basic EPS of US$0.23 sits above any single quarterly EPS figure. This supports the bullish focus on earnings momentum but also reflects the contribution from that one off item.
  • Forecasts pointing to earnings growth of about 24.9% per year lean on this track record. As a result, the bullish case is heavily supported by the margin trend but tempered by the need to strip out the US$6.8 million gain when thinking about ongoing profitability.

Margins And Growth Face A One Off Reality Check

• The trailing 12 month improvement in net profit margin to 14.3% from 13.1% sits alongside the US$6.8 million one off gain that affects those same 12 month results. Both the margin and the 32.1% earnings growth rate are therefore influenced by a non recurring boost.
• Critics highlight that a more bearish interpretation treats the US$6.8 million gain as masking the underlying trend, because once that is backed out the reported 32.1% trailing earnings growth and higher margin could look less strong relative to the five year average earnings growth of 68.9% per year.
  • Bears argue that the gap between the recent 32.1% growth and the longer run 68.9% pace already points to a slowdown and that the one off gain only complicates the picture further.
  • At the same time, the current Q1 2026 net income of US$6.3 million compares with US$7.2 million back in Q4 2024. This gives bearish investors another data point when they question how much of the recent profitability trend can be tied to the core business rather than timing or special items.

Valuation Signals Contrast With Reported Fundamentals

• At a share price of US$4.19 and a P/E of 18x that sits below both the industry at 19.7x and peers at 36.7x, the stock also trades well under the supplied DCF fair value of US$20.22. This creates a wide gap between market price and the valuation models in the data.
• Consensus narrative notes that rewards such as forecast revenue growth of about 15.7% per year and forecast earnings growth of about 24.9% per year line up with this lower P/E and DCF gap, while the presence of a US$6.8 million one off gain in the trailing numbers means investors who lean bullish on the valuation need to weigh the attractive multiples against the fact that part of the recent 32.1% earnings growth and 14.3% margin is not from recurring operations.
  • What is interesting for valuation focused readers is that the trailing 12 month revenue of US$130.4 million and net income of US$18.6 million produce the margin and P/E used in these checks. Any adjustment for the one off gain would therefore flow directly into those ratios.
  • On the other hand, the combination of lower P/E versus peers and the DCF fair value of US$20.22 compared with the US$4.19 share price is the key reason why rewards in the analysis are framed around potential upside if the forecast growth in revenue and earnings is reflected more fully in the market over time.

To see how community narratives connect these valuation signals with the latest margin and earnings trends, it is worth reading the shared viewpoints around this stock before making any decisions.Curious how numbers become stories that shape markets? Explore Community Narratives

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Niagen Bioscience's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

If this mix of positives and concerns feels balanced, that is the point. You should move quickly from reading to checking the data and forming your own view using the 3 key rewards and 1 important warning sign.

See What Else Is Out There

Niagen Bioscience's reliance on a US$6.8 million one off gain, softer recent earnings growth versus its longer run pace, and mixed quarterly net income trends may concern you.

If that mix of one off boosts and uneven earnings leaves you wanting steadier prospects, it is worth checking companies in the 72 resilient stocks with low risk scores right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.